Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "respiratory"

354 News Found

Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC
News | June 07, 2025

Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC

If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference


Paras Health Gurugram raises alarm over surge in tobacco-related cancers
News | May 31, 2025

Paras Health Gurugram raises alarm over surge in tobacco-related cancers

Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers


Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Drug Approval | May 29, 2025

Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’

Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA


Lupin to use Honeywell’s HFO technology in inhalers
News | May 21, 2025

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants


AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Diagnostic Center | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease


ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease
News | April 17, 2025

ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74


Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery
News | April 17, 2025

Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities


Shaik Barak Tulla joins Sun Pharma as Sr. VP
People | April 14, 2025

Shaik Barak Tulla joins Sun Pharma as Sr. VP

Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla


AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025
News | April 10, 2025

AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025

Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections


Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda
Healthcare | March 25, 2025

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%